{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:56:07Z","timestamp":1788944167101,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13555-024-01155-7","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T19:02:16Z","timestamp":1715281336000},"page":"1211-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Triple Combination Clindamycin Phosphate 1.2%\/Adapalene 0.15%\/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase\u00a03 Analysis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04214639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04214652","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Leon H.","family":"Kircik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil A.","family":"Tanghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe D.","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie D.","family":"Callender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sadick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary P.","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Philip","family":"Werschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"3","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","volume":"55","author":"DR Bickers","year":"2006","unstructured":"Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490\u2013500.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373.e33.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1155_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1346-8138.1991.tb03122.x","volume":"18","author":"HP Gollnick","year":"1991","unstructured":"Gollnick HP, Zouboulis CC, Akamatsu H, et al. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18(9):489\u201399.","journal-title":"J Dermatol"},{"issue":"11","key":"1155_CR4","first-page":"30","volume":"4","author":"LH Kircik","year":"2011","unstructured":"Kircik LH. Synergy and its clinical relevance in topical ance therapy. J Clin Aesth Dermaol. 2011;4(11):30\u20133.","journal-title":"J Clin Aesth Dermaol"},{"key":"1155_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2147\/PPA.S117437","volume":"10","author":"S Moradi Tuchayi","year":"2016","unstructured":"Moradi Tuchayi S, Alexander TM, Nadkarni A, Feldman SR. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016;10:2091\u20136.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/jdv.13776","volume":"30","author":"A Nast","year":"2016","unstructured":"Nast A, Dr\u00e9no B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1155_CR7","unstructured":"FDA approves Cabtreo\u2122 (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older. Bausch Health. Updated October 20, 2023. https:\/\/ir.bauschhealth.com\/news-releases\/2023\/10-20-2023. Accessed 26 Oct 2023."},{"issue":"1","key":"1155_CR8","first-page":"15","volume":"85","author":"JQ Del Rosso","year":"2010","unstructured":"Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):15\u201324.","journal-title":"Cutis"},{"issue":"3","key":"1155_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antibiotics13030270","volume":"13","author":"MK Armillei","year":"2024","unstructured":"Armillei MK, Lomakin IB, Del Rosso JQ, et al. Scientific rationale and clinical basis for clindamycin use in the treatment of dermatologic disease. Antibiotics. 2024;13(3):270.","journal-title":"Antibiotics"},{"issue":"3","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-021-00594-8","volume":"22","author":"H Baldwin","year":"2021","unstructured":"Baldwin H, Webster G, Stein Gold L, et al. 50\u00a0years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315\u201327.","journal-title":"Am J Clin Dermatol"},{"issue":"6 Pt 2","key":"1155_CR11","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/S0190-9622(97)70050-1","volume":"36","author":"B Shroot","year":"1997","unstructured":"Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96\u2013103.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1155_CR12","first-page":"5","volume":"15","author":"M Dutil","year":"2010","unstructured":"Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett. 2010;15(10):5\u20137.","journal-title":"Skin Therapy Lett"},{"issue":"5","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000093984","volume":"19","author":"JM Waller","year":"2006","unstructured":"Waller JM, Dreher F, Behnam S, et al. \u201cKeratolytic\u201d properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol. 2006;19(5):283\u20139.","journal-title":"Skin Pharmacol Physiol"},{"key":"1155_CR14","unstructured":"Antibiotic stewardship statement for antibiotic guidelines \u2013 recommendations of the HICPAC. Centers for Disease Control and Prevention. Updated December 28, 2018. https:\/\/www.cdc.gov\/hicpac\/recommendations\/antibiotic-stewardship-statement.html. Accessed 26 Oct 2023."},{"issue":"6","key":"1155_CR15","first-page":"17","volume":"9","author":"JQ Del Rosso","year":"2016","unstructured":"Del Rosso JQ, Rosen T, Thiboutot D, et al. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: current perspectives on skin and soft tissue infections with emphasis on methicillin-resistant Staphylococcus aureus, commonly encountered scenarios when antibiotic use may not be needed, and concluding remarks on rational use of antibiotics in dermatology. J Clin Aesthet Dermatol. 2016;9(6):17\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"1155_CR16","first-page":"18","volume":"9","author":"JQ Del Rosso","year":"2016","unstructured":"Del Rosso JQ, Webster GF, Rosen T, et al. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: antibiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impact of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use. J Clin Aesthet Dermatol. 2016;9(4):18\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40257-021-00650-3","volume":"23","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Baldwin H, Kircik LH, et al. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase\u00a0II study of the first triple-combination drug. Am J Clin Dermatol. 2022;23(1):93\u2013104.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaad.2022.08.069","volume":"89","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Lain E, Del Rosso JQ, et al. Clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase\u00a03 trials. J Am Acad Dermatol. 2023;89(5):927\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1365-2230.2001.00839.x","volume":"26","author":"AR Martin","year":"2001","unstructured":"Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne\u2014assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/jdv.12757","volume":"29","author":"B Dreno","year":"2015","unstructured":"Dreno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6):1096\u2013106.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1155_CR21","first-page":"21","volume":"11","author":"N Skroza","year":"2018","unstructured":"Skroza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. J Clin Aesth Dermaol. 2018;11(1):21\u20135.","journal-title":"J Clin Aesth Dermaol"},{"key":"1155_CR22","unstructured":"Clindagel\u00ae (clindamycin phosphate) Gel 1% [package insert]. Valeant, Bridgewater, NJ; 2017."},{"key":"1155_CR23","unstructured":"Tazorac\u00ae [package insert]. Allergan, Inc., Madison, NJ; 2018."},{"key":"1155_CR24","unstructured":"Altreno\u00ae [package insert]. Bausch Health Companies, Inc., Bridgewater, NJ; 1973."},{"key":"1155_CR25","unstructured":"Aklief\u00ae [package insert]. Galderma Laboratories, L.P., Fort Worth, TX; 2019."},{"key":"1155_CR26","unstructured":"Amzeeq\u00ae [package insert]. Vyne Pharmaceuticals, Inc., Bridgewater, NJ; 1971."},{"key":"1155_CR27","unstructured":"Arazlo\u00ae [package insert]. Bausch Health Companies, Inc., Bridgewater, NJ; 1997."},{"key":"1155_CR28","unstructured":"Winlevi\u00ae [package insert]. Cassiopea, Inc., Milan, Italy; 2020."},{"key":"1155_CR29","unstructured":"Differin\u00ae [package insert]. Galderma Laboratories, L.P., Fort Worth, TX; 1996."},{"issue":"4","key":"1155_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1370\/afm.2995","volume":"21","author":"CY Huang","year":"2023","unstructured":"Huang CY, Chang IJ, Bolick N, et al. Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials. Ann Fam Med. 2023;21(4):358\u201369.","journal-title":"Ann Fam Med"},{"issue":"4","key":"1155_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2310\/7750.2006.00044","volume":"10","author":"JK Tan","year":"2006","unstructured":"Tan JK, Fung K, Bulger L. Reliability of dermatologists in acne lesion counts and global assessments. J Cutan Med Surg. 2006;10(4):160\u20135.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1155_CR32","first-page":"110","volume":"84","author":"LS Gold","year":"2009","unstructured":"Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110\u20136.","journal-title":"Cutis"},{"issue":"1","key":"1155_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00128071-200102010-00006","volume":"2","author":"JJ Leyden","year":"2001","unstructured":"Leyden JJ, Berger RS, Dunlap FE, et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol. 2001;2(1):33\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1155_CR34","first-page":"1083","volume":"13","author":"DM Pariser","year":"2014","unstructured":"Pariser DM, Rich P, Cook-Bolden FE, Korotzer A. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1155_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40257-016-0178-4","volume":"17","author":"L Stein Gold","year":"2016","unstructured":"Stein Gold L, Weiss J, Rueda MJ, et al. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %\/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293\u2013303.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1155_CR36","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaad.2008.06.040","volume":"59","author":"D Thiboutot","year":"2008","unstructured":"Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59(5):792\u2013800.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1155_CR37","first-page":"165","volume":"67","author":"EH Tschen","year":"2001","unstructured":"Tschen EH, Katz HI, Jones TM, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001;67(2):165\u20139.","journal-title":"Cutis"},{"issue":"6","key":"1155_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/der2.49","volume":"2","author":"EM Graber","year":"2021","unstructured":"Graber EM. Treating acne with the tetracycline class of antibiotics: a review. Dermatol Rev. 2021;2(6):321\u201330.","journal-title":"Dermatol Rev"},{"issue":"2","key":"1155_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.36849\/JDD.7927","volume":"23","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Han G, Callender VD, et al. Benefit of topical combination therapy for acne: analyzing effect size using number needed to treat. J Drugs Dermatol. 2024;23(2):42\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1155_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1525-1470.2011.01643.x","volume":"28","author":"JL Goldberg","year":"2011","unstructured":"Goldberg JL, Dabade TS, Davis SA, et al. Changing age of acne vulgaris visits: another sign of earlier puberty? Pediatr Dermatol. 2011;28(6):645\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1155_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jdermsci.2019.01.007","volume":"93","author":"C Kumtornrut","year":"2019","unstructured":"Kumtornrut C, Yamauchi T, Koike S, et al. Androgens modulate keratinocyte differentiation indirectly through enhancing growth factor production from dermal fibroblasts. J Dermatol Sci. 2019;93(3):150\u20138.","journal-title":"J Dermatol Sci"},{"issue":"Suppl 5","key":"1155_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jdv.13188","volume":"29","author":"B Dr\u00e9no","year":"2015","unstructured":"Dr\u00e9no B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015;29(Suppl 5):14\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1155_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.36849\/JDD.6876","volume":"21","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Kircik L, Baldwin H, et al. Tazarotene 0.045% lotion for females with acne: analysis of two adult age groups. J Drugs Dermatol. 2022;21(6):587\u201395.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1155_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jamadermatol.2014.5254","volume":"151","author":"KL Anderson","year":"2015","unstructured":"Anderson KL, Dothard EH, Huang KE, Feldman SR. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623\u20136.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1155_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-4632.2010.04416.x","volume":"49","author":"B Dr\u00e9no","year":"2010","unstructured":"Dr\u00e9no B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448\u201356.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1155_CR46","first-page":"s148","volume":"18","author":"LH Kircik","year":"2019","unstructured":"Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):s148\u201354.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1155_CR47","first-page":"22","volume":"7","author":"EA Tanghetti","year":"2014","unstructured":"Tanghetti EA, Kawata AK, Daniels SR, et al. Understanding the burden of adult female acne. J Clin Aesthet Dermatol. 2014;7(2):22\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"20","key":"1155_CR48","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2021.17633","volume":"326","author":"DZ Eichenfield","year":"2021","unstructured":"Eichenfield DZ, Sprague J, Eichenfield LF. Management of acne vulgaris: a review. JAMA. 2021;326(20):2055\u201367.","journal-title":"JAMA"},{"issue":"3","key":"1155_CR49","first-page":"125","volume":"23","author":"JC Harper","year":"2024","unstructured":"Harper JC, Kircik LH, Gold M, et al. Early and sustained acne lesion reductions with fixed-dose clindamycin phosphate 1.2%\/adapalene 0.15%\/benzoyl peroxide 3.1% gel. J Drugs Dermatol. 2024;23(3):125\u201331.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01155-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:29:05Z","timestamp":1716470945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01155-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Leon H. Kircik has served as either a consultant, speaker, advisor or an investigator for Allergan, Almirall, Epi Health, Galderma, Novartis, Ortho Dermatologics, and Sun Pharma. Linda Stein Gold has served as investigator\/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis, and Lilly. Michael Gold has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. Jonathan S. Weiss is a consultant, speaker, advisor, and\/or researcher for AbbVie, Ortho Dermatologics, Janssen Biotech, Dermira, Almirall, Brickell Biotech, DermTech, and Scynexis. Julie C. Harper has received honoraria from Aclaris, Almirall, BioPharmX, Cassiopea, Cutanea, Dermira, Foamix, Galderma, LaRoche-Posay, Ortho Dermatologics, and Sun Pharma. James Q. Del Rosso has served as a consultant, investigator, and\/or speaker for Ortho Dermatologics, AbbVie, Amgen, Arcutis, Cutera, Dermavant, EPI Heath, Galderma, Incyte, JEM Health, La Roche-Posay, LEO Pharma, Lilly, L\u2019Oreal, MC2 Therapeutics, Pfizer, Strata, Sun Pharma, and UCB. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Timber, and Palvella; a consultant for AbbVie, Almirall, Apogee, Arcutis, Eli Lilly, EPI Health\/Novan, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB; and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. Neal Bhatia has served as advisor, consultant, and investigator for AbbVie, Almirall, Biofrontera, BI, Brickell, BMS, EPI Health, Ferndale, Galderma, InCyte, ISDIN, J&J, LaRoche-Posay, LEO Pharma, Ortho Dermatologics, Regeneron, Sanofi, Sun Pharma, Verrica, and Vyne. Emil A. Tanghetti has served as speaker for Novartis, Ortho Dermatologics, Sun Pharma, Lilly, Galderma, AbbVie, and Dermira; served as a consultant\/clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure. Lawrence F. Eichenfield has received honoraria for consulting services from AbbVie, BMS, Dermata, Dermira, Dermavant, Eli Lilly, Forte Pharma, Galderma, Incyte, J&J, Otsuka, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Ortho Dermatologics; and study support (to institution) from AbbVie, Bausch Health, Dermira, Eli Lilly and Company, Galderma, Incyte, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. Hilary Baldwin has served as advisor, investigator, and on speakers\u2019 bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. Zoe D. Draelos received funding from Ortho Dermatologics. Valerie D. Callender has served as an investigator, consultant, or speaker for Acne Store, Almirall, Aerolase, AbbVie, Allergan Aesthetics, Avava, Avita Medical, Beiersdorf, Cutera, Dermavant, Eli Lilly, Epi Health, Galderma, Janssen, Jeune Aesthetics, L\u2019Or\u00e9al, Ortho Dermatologics, Pfizer, Prollineum, Regeneron, Scientis, Sente, SkinBetter science, SkinCeuticals, Symatese, UCB, and UpToDate. George Han is or has been an investigator, consultant\/advisor, or speaker for AbbVie, Athenex, Boehringer Ingelheim, Bond Avillion, Bristol-Myers Squibb, Celgene, Eli Lilly, Novartis, Janssen, LEO Pharma, MC2, Ortho Dermatologics, PellePharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. Melinda J. Gooderham has served as investigator\/consultant or speaker for AbbVie, Akros Pharma, Amgen, Arcutis Biotherapeutics, Aslan, Aristea, AnaptysBio, Bausch, BMS, Boehringer Ingelheim, Coherus BioSciences, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Inmagene, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Reistone, Roche, Sanofi, Sun Pharma, Takeda, Tarsus, Union, UCB and Ventyx. Neil Sadick has served on advisory boards, as a consultant, investigator, speaker, and\/or other and has received honoraria and\/or grants\/research funding from Almirall, Actavis, Allergan, Anacor Pharmaceuticals, Auxilium Pharmaceuticals, Bausch Health, Bayer, Biorasi, BTG, Carma Laboratories, Cassiopea, Celgene Corporation, Cutera, Cynosure, DUSA Pharmaceuticals, Eclipse Medical, Eli Lilly and Company, Endo International, EndyMed Medical, Ferndale Laboratories, Galderma, Gerson Lehrman Group, Hydropeptide, Merz Aesthetics, Neostrata, Novartis, Nutraceutical Wellness, Palomar Medical Technologies, Prescriber's Choice, Regeneron, Roche Laboratories, Samumed, Solta Medical, Storz Medical AG, Suneva Medical, Vanda Pharmaceuticals, and Venus Concept. Mary P. Lupo has served as a speaker, investigator, and\/or on advisory boards for Ortho Dermatologics, Bausch Health US, Evolus, Revance, Eirion, Prolennium, Chemocentryx, Therapeutics Incorporated, Brickell, Endo, Cutera, In Mode, Revision, and Merz. Edward\u00a0(Ted) Lain has served as investigator, consultant and\/or speaker for Ortho Dermatologics, AbbVie, Almirall, Amgen, Arcutis, Dermavant, EPI Health, Galderma, Incyte, LEO Pharma, Novartis, Eli Lilly, Pfizer, Sun Pharma, UCB, Endo International, ChemoCentryx, Biorasi, Sirnaomics, Evelo Biosciences, Concert Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Mindera, Biofrontera, Alfasigma, AiViva Biopharma, Anaptys Bio, Bausch Health, Dr Reddy\u2019s, Trevi Therapeutics. William Philip Werschler has served as an investigator for Ortho Dermatologics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were carried out in accordance with principles of Good Clinical Practice (GCP) and the Declaration of Helsinki. Study protocols across all study centers were approved by the same central institutional review board (Advarra IRB, Columbus, MD, USA). All participants or their legal guardians provided written informed consent before entering the clinical trial from which the data were derived. Additional informed consent was obtained from all individual participants for whom identifying information\/photographs are included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}